"""
Question: 1101 

Evidence: Here, we explored how preexisting NRTI resistance mutations affect the development of EFdA resistance. We selected viruses resistant to EFdA by serial passage of HIV-1 that was either WT or resistant to TFV (K65R), 3TC/FTC (M184V), or AZT (D67N/K70R/T215F/K219Q)

Rationale: The paper describes original experimental work performing serial passaging and analyzing resistance, indicating it reports new, previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162. PCR was performed … to generate a 2,127-bp product spanning the full length of the reverse transcriptase gene

Rationale: The paper sequenced HIV-1 reverse transcriptase from passaged viruses and deposited the resulting sequences in GenBank, confirming it reports HIV sequences.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Serial passages were initiated by infecting MT-2 cells with WT (xxLAI), K65R, M184V, or D67N/K70R/T215F/K219Q stock virus in the presence of EFdA and monitored as described in Materials and Methods. In every case, the passaged viruses were able to replicate in the presence of greater EFdA concentrations than the parental virus, indicating that some degree of EFdA resistance had developed

Rationale: These sentences describe in vitro serial passaging of HIV-1 in increasing EFdA concentrations and the observed breakthrough, i.e., the results of in vitro passage experiments.

Answer: Yes
"""

"""
Question: 1104 

Evidence: To evaluate the degree of resistance selected in the passaging experiments, sensitivity to EFdA was determined for virus supernatants from passage 6 onward. To determine whether the various EFdA resistance mutations are susceptible to approved drugs such as tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), we prepared dose-response curves

Rationale: The study measured dose-response (EC50) to EFdA, TDF, and FTC in cell-based assays, which are in vitro antiretroviral susceptibility data.

Answer: Yes
"""

"""
Question: 2101 

Evidence: Mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162. The P0 consensus sequences from each virus were aligned … and 500 ng of sample was submitted … for full-length, double-stranded population sequencing

Rationale: The paper explicitly provides GenBank accession numbers for the sequences obtained.

Answer: Yes
"""

"""
Question: 2102 

Evidence: Serial passages were initiated by infecting MT-2 cells with WT (xxLAI), K65R, M184V, or D67N/K70R/T215F/K219Q stock virus in the presence of EFdA. Mutation sequences … have been deposited in GenBank under accession no. OK263149 to OK263162

Rationale: All sequences were derived from laboratory passaging of lab HIV-1 strains and molecular clones; there were no clinical isolates. Therefore, no accession numbers for non-laboratory isolates were reported.

Answer: No
"""

"""
Question: 2103 

Evidence: Mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162

Rationale: The paper lists a contiguous range of GenBank accession numbers for the submitted sequences.

Answer: OK263149 to OK263162
"""

"""
Question: 2202 

Evidence: Clonal sequencing … was carried out on clones from various passages to identify any changes in RT that may have arisen during replication in the presence of EFdA. Table 1 summarizes the data … for isolates … listing amino acid mutation(s) and the proportion of the sequence population

Rationale: The study presents lists of mutations per passaged virus sample (and clone proportions) in Table 1, i.e., mutation lists for sequenced isolates.

Answer: Yes
"""

"""
Question: 2301 

Evidence: Development of Human Immunodeficiency Virus Type 1 Resistance to 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine. Serial passages were initiated by infecting MT-2 cells with WT (xxLAI)… stock virus in the presence of EFdA

Rationale: The title and methods make clear the experiments were conducted with HIV-1 laboratory strains.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Serial passages were initiated by infecting MT-2 cells with WT (xxLAI) … and relevant molecular clones in a WT (NL4-3) backbone. The paper does not state the subtype of these laboratory strains

Rationale: Although LAI and NL4-3 are commonly subtype B, the paper does not explicitly provide subtypes for the sequenced viruses; therefore, the subtype cannot be determined from the text.

Answer: NA
"""

"""
Question: 2303 

Evidence: PCR … generate a 2,127-bp product spanning the full length of the reverse transcriptase gene. Clonal sequencing of full-length reverse transcriptase gene PCR products

Rationale: The sequenced region was the full-length reverse transcriptase gene.

Answer: Reverse transcriptase (RT) gene
"""

"""
Question: 2304 

Evidence: PCR … generate a 2,127-bp product spanning the full length of the reverse transcriptase gene. Clonal sequencing of full-length reverse transcriptase gene PCR products

Rationale: The reverse transcriptase gene is part of the HIV pol region; thus, the paper reports results of HIV pol (RT) sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Serial passages were initiated by infecting MT-2 cells … with stock virus in the presence of EFdA. Mutation sequences … deposited in GenBank under accession no. OK263149 to OK263162

Rationale: Sequences were derived from in vitro laboratory passaging rather than from human subjects tied to geographic locations; no geographic origin is provided.

Answer: NA
"""

"""
Question: 2402 

Evidence: Viral RNA was purified from supernatants … and submitted … for full-length, double-stranded population sequencing. The paper does not specify years of sample collection

Rationale: The study involves lab-generated samples without reported collection dates; hence years cannot be determined.

Answer: NA
"""

"""
Question: 2502 

Evidence: 500 ng of sample was submitted … for full-length, double-stranded population sequencing. Clonal sequencing … ligated into the pGEM-T vector … and a minimum of 20 clones from each sample were sequenced with primers

Rationale: The described workflow (population sequencing and sequencing of cloned inserts using primers) corresponds to Sanger sequencing, not NGS.

Answer: Yes
"""

"""
Question: 2503 

Evidence: 500 ng of sample was submitted … for full-length, double-stranded population sequencing. Clonal sequencing … ligated into the pGEM-T vector … and sequenced with primers

Rationale: No next-generation sequencing technology is mentioned; the methods reflect Sanger-based population and clone sequencing.

Answer: No
"""

"""
Question: 2504 

Evidence: Approximately 105 ng of full-length PCR product was ligated into the pGEM-T vector … Ligations were transformed … and a minimum of 20 clones from each sample were sequenced. Clonal sequencing of full-length reverse transcriptase gene PCR products

Rationale: The RT PCR products were cloned into a plasmid vector prior to sequencing.

Answer: Yes
"""

"""
Question: 2505 

Evidence: Population and clonal sequencing of viral RNA from passage supernatants were performed. Approximately 105 ng of full-length PCR product was ligated into the pGEM-T vector … and clones were sequenced

Rationale: They performed TA cloning and sequencing of multiple clones, not single-genome sequencing from limiting dilution.

Answer: No
"""

"""
Question: 2506 

Evidence: Emory's Cloning Core was used to make individual mutants in the backbone of NL4.3. Approximately 105 ng of full-length PCR product was ligated into the pGEM-T vector … and clones were sequenced

Rationale: The study involved molecular cloning to create site-directed mutant viruses and cloning of PCR products for sequencing.

Answer: Yes
"""

"""
Question: 2601 

Evidence: Viral RNA was purified from supernatants using the QIAamp Viral RNA minikit … and used as the template for cDNA synthesis. Serial passages were initiated by infecting MT-2 cells … with stock virus in the presence of EFdA

Rationale: Sequencing was performed on viral RNA from culture supernatants, not from human plasma.

Answer: No
"""

"""
Question: 2602 

Evidence: Viral RNA was purified from supernatants … and used as the template for cDNA synthesis. The study uses MT-2, TZM-GFP, P4-R5 MAGI, and other cell lines

Rationale: No PBMC-derived sequencing is reported.

Answer: No
"""

"""
Question: 2603 

Evidence: Viral RNA was purified from supernatants … and used as the template for cDNA synthesis. No human plasma samples are described

Rationale: The study did not sequence plasma virus from individuals, so the count is zero.

Answer: 0
"""

"""
Question: 2604 

Evidence: The study uses established cell lines (MT-2, TZM-GFP, P4-R5 MAGI) for passaging and assays. No PBMC samples are described

Rationale: No PBMC sequencing was done; therefore, zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: Serial passages were initiated by infecting MT-2 cells with … stock virus in the presence of EFdA. Viral RNA was purified from supernatants … for sequencing

Rationale: Sequences were from laboratory cultures, not from individuals with ongoing HIV replication.

Answer: No
"""

"""
Question: 2606 

Evidence: Viral RNA was purified from supernatants … and used as the template for cDNA synthesis. The paper does not report sequencing of cellular proviral DNA

Rationale: Sequencing was done from extracellular viral RNA, not from proviral DNA reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: The experiments were conducted in cell lines (MT-2, TZM-GFP, P4-R5 MAGI) and with molecular clones. No human subjects are described

Rationale: There were no human samples, including from infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: The study is an in vitro selection and molecular cloning study using cell lines. No clinical participants or trials are described

Rationale: There were no individuals enrolled in clinical trials.

Answer: No
"""

"""
Question: 2703 

Evidence: The study involves only in vitro experiments in cell lines and molecular clones. No human subjects were enrolled

Rationale: With no individuals in the study, the question is not applicable.

Answer: NA
"""

"""
Question: 3101 

Evidence: Viral RNA was purified from supernatants … of passaged virus cultures. No human subjects or individual patient samples are described

Rationale: Sequencing was performed on lab cultures, so zero individuals had samples sequenced.

Answer: 0
"""

"""
Question: 3102 

Evidence: No human subjects are included; all work used cell lines and molecular clones. Sequencing targeted lab-passaged virus populations and clones

Rationale: Since there were no individuals, the question is not applicable.

Answer: NA
"""

"""
Question: 4101 

Evidence: The paper reports sequences from in vitro passaged laboratory HIV-1. No human subjects or their ART status are reported

Rationale: Therefore, it does not report sequences from ART-naive individuals.

Answer: No
"""

"""
Question: 4102 

Evidence: The paper reports sequences from in vitro passaged laboratory HIV-1. No human subjects or prior ARV exposure are reported

Rationale: Therefore, it does not report sequences from ART-experienced individuals.

Answer: No
"""

"""
Question: 4103 

Evidence: The study is entirely in vitro using lab strains and cell lines. No individuals with ART histories are included

Rationale: Thus, it does not report sequences from ART-naive or ART-experienced individuals.

Answer: No
"""

"""
Question: 4104 

Evidence: No human subjects are described; sequencing was done on lab-passaged virus. Therefore, there are no ART-naive individuals sampled

Rationale: The number of samples from ART-naive individuals is zero.

Answer: 0
"""

"""
Question: 4105 

Evidence: The study does not include human participants or their treatment histories. It is an in vitro study in cell lines

Rationale: With no individuals, ART histories cannot be provided.

Answer: NA
"""

"""
Question: 4201 

Evidence: The study focuses on in vitro selection of resistance and molecular analyses. No epidemiologic data on transmitted resistance are provided

Rationale: There is no prevalence information on transmitted drug resistance.

Answer: No
"""

"""
Question: 4202 

Evidence: The study involves laboratory passaging and molecular cloning. No data on pretreatment resistance prevalence in patients are presented

Rationale: There is no prevalence information on pretreatment resistance.

Answer: No
"""

"""
Question: 4301 

Evidence: No individuals were treated; the paper tested viruses against EFdA, TDF, and FTC in vitro. The Introduction mentions HAART drug classes generally but not patient treatments in this study

Rationale: Since there are no individuals, no ART classes were received.

Answer: NA
"""

"""
Question: 4302 

Evidence: The study does not include human subjects or treatment regimens. It reports only in vitro assays

Rationale: Therefore, no information on individuals receiving integrase inhibitors is reported.

Answer: No
"""

"""
Question: 4303 

Evidence: The study does not include human subjects or treatment regimens. It reports only in vitro assays

Rationale: Therefore, no information on individuals receiving protease inhibitors is reported.

Answer: No
"""

"""
Question: 4304 

Evidence: There are no individuals in the study; only cell-based experiments and molecular clones are described. No ART regimens are administered

Rationale: The question is not applicable without individuals.

Answer: NA
"""

"""
Question: 4305 

Evidence: The study lacks human participants and treatment histories. It is an in vitro experiment using cell lines

Rationale: INSTI-naivety of individuals cannot apply.

Answer: NA
"""

"""
Question: 4403 

Evidence: No human participants or ART regimens are described. All work was done in vitro

Rationale: Consequently, zero individuals received more than one ART regimen.

Answer: 0
"""

"""
Question: 4404 

Evidence: No human participants or ART regimens are described. All work was done in vitro

Rationale: Consequently, zero individuals received more than two ART regimens.

Answer: 0
"""

"""
Question: 4405 

Evidence: There are no individuals in the study. It involves laboratory virus and cell lines

Rationale: The question is not applicable.

Answer: NA
"""

"""
Question: 4406 

Evidence: The study includes no human subjects or ART administration. It is entirely in vitro

Rationale: Therefore, not all individuals received one ART regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: No human subjects or clinical treatments are reported. The study is in vitro

Rationale: Therefore, zero individuals received dolutegravir.

Answer: 0
"""

"""
Question: 4502 

Evidence: No human subjects or clinical treatments are reported. The study is in vitro

Rationale: Therefore, zero individuals received darunavir.

Answer: 0
"""

"""
Question: 5101 

Evidence: There are no human subjects in the study. Sequencing pertains to lab-passaged viruses and clones

Rationale: Thus, zero individuals were found to have drug resistance mutations.

Answer: 0
"""

"""
Question: 5102 

Evidence: No individuals were studied clinically, and no integrase sequencing is reported. The focus is on reverse transcriptase

Rationale: Therefore, zero individuals had INSTI-resistance mutations.

Answer: 0
"""

"""
Question: 5103 

Evidence: No human subjects were included. The study reports hypersusceptibility to tenofovir for certain mutants but not patient-derived TDF resistance

Rationale: Therefore, zero individuals were found to have TDF-resistance mutations.

Answer: 0
"""

"""
Question: 5104 

Evidence: No human subjects or integrase inhibitor exposure are described. Sequencing was of the reverse transcriptase gene, not integrase

Rationale: No INSTI-resistance mutations in individuals were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: TZM-GFP cells were pretreated with EFdA and infected after 24 h. P4-R5 MAGI cells were treated with various concentrations of EFdA and infected … after 48 h, the cells were lysed, and the β-galactosidase activity was assessed

Rationale: Phenotypic susceptibility was measured using cell-based dose-response assays in TZM-GFP (GFP readout) and P4-R5 MAGI (β-gal) cells.

Answer: Cell-based dose-response infectivity assays using TZM-GFP (GFP readout) and P4-R5 MAGI (β-galactosidase) cells
"""

"""
Question: 6102 

Evidence: Steady-state kinetics and in vitro IC50s. EC50 curves were then determined using Prism 5 (GraphPad) software

Rationale: The methods section mentions in vitro IC50s and the study reports EC50 values for drug susceptibility, indicating reporting of IC/EC metrics.

Answer: Yes
"""

"""
Question: 6103 

Evidence: Table 2 EC50 fold change compared to WT (NL4-3). Mean EC50 fold change ± the SD

Rationale: The paper reports EC50 fold changes, not IC50 fold changes.

Answer: No
"""

"""
Question: 6104 

Evidence: TZM-GFP cells were pretreated with EFdA and infected after 24 h… GFP-positive cells were then counted. P4-R5 MAGI cells were treated with various concentrations of EFdA and infected … β-galactosidase activity was assessed

Rationale: These are standard cell-based phenotypic susceptibility assays measuring infection via GFP or β-gal readouts.

Answer: TZM-GFP GFP-based infectivity assay and P4-R5 MAGI β-galactosidase infectivity assay
"""

"""
Question: 6105 

Evidence: To determine the effect of mutations on viral fitness, we tested viruses in single-cycle replication assays known as specific infectivity. M184V … showed a significant decrease in specific infectivity

Rationale: Specific infectivity measurements reflect replication capacity; the paper reports these data.

Answer: Yes
"""

"""
Question: 6106 

Evidence: Dose response of EFdA-passaged viruses to EFdA. To determine whether the various EFdA resistance mutations are susceptible to approved drugs such as tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), we prepared dose-response curves

Rationale: The phenotypic susceptibility assays tested EFdA (islatravir), TDF, and FTC.

Answer: EFdA (islatravir), tenofovir disoproxil fumarate (TDF), and emtricitabine (FTC)
"""

"""
Question: 7101 

Evidence: Mutations were introduced into NL4-3. Emory's Cloning Core was used to make individual mutants in the backbone of NL4.3

Rationale: The paper constructed site-directed mutant molecular clones.

Answer: Yes
"""

"""
Question: 7102 

Evidence: Serial passages were initiated by infecting MT-2 cells with WT (xxLAI), K65R, M184V, or D67N/K70R/T215F/K219Q stock virus in the presence of EFdA. In every case, the passaged viruses were able to replicate in the presence of greater EFdA concentrations than the parental virus, indicating that some degree of EFdA resistance had developed

Rationale: Many of the isolates studied arose from in vitro serial passage in EFdA.

Answer: Yes
"""